<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04819841</url>
  </required_header>
  <id_info>
    <org_study_id>GPH101-001</org_study_id>
    <nct_id>NCT04819841</nct_id>
  </id_info>
  <brief_title>Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease</brief_title>
  <acronym>CEDAR</acronym>
  <official_title>A Phase I/II Study of the Correction of a Single Nucleotide Mutation (Adenosine --&gt; Thymine [A--&gt;T]) in Autologous CD34+ Hematopoietic Stem Cells to Convert HbS to HbA for Treating Severe Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Graphite Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Graphite Bio, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a first-in-human, single-arm, open-label Phase I/II study of GPH101 in&#xD;
      approximately 15 participants, diagnosed with severe Sickle Cell Disease. The primary&#xD;
      objective is to evaluate safety of the treatment in this patient population, as well as&#xD;
      preliminary efficacy and pharmacodynamic data.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants diagnosed with severe SCD will receive GPH101 via IV infusion following&#xD;
      myeloablative conditioning in an autologous HSCT setting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">May 2026</completion_date>
  <primary_completion_date type="Anticipated">May 2026</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success of HSC engraftment</measure>
    <time_frame>42 days post-infusion</time_frame>
    <description>proportion of participants who reach neutrophil engraftment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Transplant-related mortality</measure>
    <time_frame>100 days post-infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Transplant-related mortality</measure>
    <time_frame>12 months post-infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months post-infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of AEs/SAEs</measure>
    <time_frame>24 months post-infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone marrow HSPC or peripheral myeloid gene correction marking</measure>
    <time_frame>24 months post-infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total HbS without disease-indicated transfusion support for ≥3 continuous months</measure>
    <time_frame>24 months post-infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total HbA without disease-indicated transfusion support for ≥3 continuous months</measure>
    <time_frame>24 months post-infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Hgb without disease-indicated transfusion support for ≥3 continuous months</measure>
    <time_frame>24 months post-infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in annualized packed red blood cell (pRBC) transfusion requirements (volume and frequency) for SCD indications</measure>
    <time_frame>6 and 24 months post-infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of vaso-occlusive crises (VOC), Acute Chest Syndrome (ACS) episodes, and other SCD-related events compared to the 2 years prior to enrollment as documented by a visit to a medical facility</measure>
    <time_frame>24 months post-infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in transcranial Doppler (TCD) velocity in applicable participants with available TCD assessments</measure>
    <time_frame>24 months post-infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in SCD-indicated lab parameters, including but not limited to bilirubin, reticulocyte counts, erythropoietin, LDH, eGFR, haptoglobin, CRP</measure>
    <time_frame>24 months post-infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of globin chain expression</measure>
    <time_frame>1, 2, 3, 6, 9, 12, 15, 18, 21, and 24 months post-infusion</time_frame>
    <description>hemoglobin fractions as percent of total</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>GPH101 Drug Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GPH101 Drug Product is a human autologous CRISPR-Cas9 edited and sickle mutation-corrected HSPC product.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>GPH101 Drug Product</intervention_name>
    <description>GPH101 is administered via IV infusion following a myeloablative conditioning regimen</description>
    <arm_group_label>GPH101 Drug Product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥12 to ≤ 40 years&#xD;
&#xD;
          -  Severe disease, as defined by having experienced at least one of the following&#xD;
             SCD-related events despite appropriate supportive care measures:&#xD;
&#xD;
          -  recurrent severe VOC (≥ 4 episodes in the preceding 2 years)&#xD;
&#xD;
          -  ACS (≥ 2 episodes in the prior 2 years with at least one episode in the past year)&#xD;
&#xD;
          -  Lansky/Karnofsky performance status of ≥ 80&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Available 10/10 HLA-matched donor&#xD;
&#xD;
          -  Prior HSCT or gene therapy&#xD;
&#xD;
          -  Prior or current malignancy or myeloproliferative or a significant coagulation or&#xD;
             immunodeficiency disorder&#xD;
&#xD;
          -  Clinically significant and active bacterial, viral, fungal or parasitic infection&#xD;
&#xD;
          -  Pregnancy or breastfeeding in a postpartum female&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandria Petrusich</last_name>
    <role>Study Director</role>
    <affiliation>Graphite Bio, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allison Intondi, PhD</last_name>
    <phone>650-484-0886</phone>
    <email>clinicaltrials@graphitebio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Intake Team</last_name>
      <phone>650-723-0912</phone>
      <email>scgt_clinical_trials_office@lists.stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Matthews</last_name>
      <phone>314-273-3983</phone>
      <email>matthewsm@wustl.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 24, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sickle cell disease</keyword>
  <keyword>sickle cell anemia</keyword>
  <keyword>gene correction</keyword>
  <keyword>gene therapy</keyword>
  <keyword>CRISPR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

